Abiopharma

🔍 Guido James (Executive)

Company: J.Jill, Inc. (JILL)

Report Date: 2026-04-28

Detailed Transactions and Holdings:

• Acquired 57 shares of Common Stock (Direct)
  Date: 2026-04-28 | Code: J | equity_swap_involved: false | shares_owned_after: 13,091.50 | transaction_form_type: 4 | Footnotes: F1, F1
• Acquired 34 shares of Performance Stock Units (Derivative)
  Date: 2026-04-28 | Code: A | equity_swap_involved: false | shares_owned_after: 4,605.19 | transaction_form_type: 4 | Footnotes: F3, F1, F3, F3

Footnotes:

• F1: On April 28, 2026, J.Jill, Inc. paid a cash dividend of $0.09 per share on each share of its outstanding common stock, par value $0.01 per share ("Common Stock"). The dividend was payable to all holders of Common Stock on the record date, April 14, 2026. Pursuant to the terms of the agreements governing the outstanding restricted stock units held by the filer, the filer received certain additional restricted stock units as a result of this cash dividend. These additional units are subject to the same conditions regarding vesting and settlement as the underlying restricted stock units to which they relate.
• F2: This represents 51.15 restricted stock units and 5.5 shares of performance stock units earned based on J.Jill, Inc. achieving a predetermined Adjusted EBITDA threshold.
• F3: This represents Mr. Guido's performance stock units that will be eligible for vesting based on achievement of absolute total shareholder return compound annual growth rate goals ("TSR PSUs") and settlement as the underlying performance stock units to which they relate. Each TSR PSU represents the contingent right to receive, upon vesting, one share of Common Stock and the number of TSR PSUs reported represents the maximum possible number of shares of Common Stock that are eligible for vesting.